Fed-batch production and development of cell lysis for recovery of an E. coli recombinant staphylococcal endolysin to fight against antimicrobial resistant S. aureus
Summary
Biopharmaceutical Biotechnology
Public
Micreos GmbH, Zugerstrasse 76, Wädenswil, CH-8820, Switzerland
Carmen Jungo Rhême
Skills directory
March 2024 - July 2024
A cell lysis step by sonication for the recovery of an E. coli recombinant staphylococcal peptidoglycan hydrolase was developed and optimized. The recombinant endolysin (a type of peptidoglycan hydrolase) was expressed in high cell density E. coli fed-batch cultures.
In this project recombinant anti-staphylococcal endolysins are produced using an E. coli strain from the company Micreos GmbH, a biotech developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.
After growth of the recombinant E. coli strain in batch and fed-batch phase, the expression of the endolysin is induced by the addition of IPTG in fed-batch mode.
The main goals of this project were to implement successful fed-batch cultures and the development and optimization of a cell lysis step by sonication. Cell lysis is an essential first purification step for any recombinant protein expressed intracellularly. Sonication is used to break apart the cell wall, releasing intracellular and transmembrane proteins into solution for downstream purification.